Press Release

Morphic Announces Participation in 2022 RBC Capital Markets Global Healthcare Conference

May 17, 2022 at 8:01 AM EDT

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside chat at the RBC Capital Markets on Wednesday, May 18that 8:00 AM ET.

A live webcast of the event will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com 
617.686.1718